Eli Lilly and Company Gets A Huge Blow As FDA OKs Cymbalta Generics

The U.S. Food and Drug Administration on Wednesday approved generic versions of Eli Lilly and Co's antidepressant Cymbalta, the U.S. drugmaker's biggest-selling product. The drug, which has annual sales of about $5 billion, was expected to lose patent protection this month. The FDA said it approved cheaper versions of the drug, known chemically as duloxetine, in a variety of strengths for sale by several generic drugmakers, including Teva Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, Sun Pharmaceutical Industries and Torrent Pharmaceuticals Ltd.

Help employers find you! Check out all the jobs and post your resume.